Analysis of hsa-miR-30a-5p and hsa-miR-200c-3p microRNA expression in brain tumor

  • I. Ya. Skrypkina
  • K. V. Onyshchenko
  • D. О. Gerasymchuk
  • O. V. Anopriyenko
  • P. O. Areshkov
DOI: https://doi.org/10.7124/FEEO.v24.1106

Abstract

Aim. Despite scientific and clinical success, glioblastoma remains the most aggressive tumor of the brain with extremely low prognostic potential for the patient. Biomarkers determining prognosis, and hence a treatment strategy, remains an actual problem at the moment. miRNAs can be considered as markers of glioblastoma. World’s long-term study confirm the legitimacy of miRNAs usage as reliable markers for the tumors diagnosis and prognosis, in particular brain tumors. The purpose of our study was miRNAs targeting, the change in expression of which in gliomas can be reliably associated with malignancy degree and tumor progression. Methods. To achieve the purpose of the investigation there were used such methods as bioinformatics search of the miRNAs for 3’-UTR genes associated with gliomas development, RNA isolation and miRNA-specific synthesis of cDNAs. The expression levels of miRNAs were determined by the real-time quantitative PCR (qPCR). The relative expression levels of targeted miRNAs were evaluated by comparing their content in tumor and adjacent tissues, conditionally healthy brain tissues of the same patients. Results. The analysis of qPCR results showed a decreased concentration of miR-30a-5p and miR-200c-3p in brain tumors relative to adjacent normal tissue in average of the 5 and 5.8 times, respectively (p <0.0001). Area under the ROC curve analysis of miR-30a-5p was AUC = 0.88528, for miR-200c-3p - AUC = 0.808. Conclusions. As an additional diagnostic and prognostic marker of glibalastoma signature determination, the expression level of hsa-miR-30a-3p and hsa-miR-200c-3p showed a good diagnostic potential (AUC = 7-9).

Keywords: glioblastoma, microRNA, hsa-miR-30a-5p, hsa-miR-200c-3p.

References

MacFarlane L.A., Murphy P.R. MicroRNA: biogenesis, function and role in cancer. Current Genomics. 2010. Vol. 11. P. 537–561. doi: 10.2174/138920210793175895.

Esquela-Kerscher A., Slack F.J. Oncomirs – microRNAs with a role in cancer. Nature Reviews Cancer. 2006. Vol. 6. P. 259–269. doi: 10.1038/nrc1840.

Hwang H.W., Mendell J.T. MicroRNAs in cell proliferation, cell death, and tumorigenesis. 2006. Vol. 94. P. 776–780. doi: 10.1038/sj.bjc.6603023.

Dalmay T., Edwards D.R. MicroRNAs and the hallmarks of cancer. 2006. Vol. 25. P. 6170–6175. doi: 10.1038/sj.onc.1209911.

Esau C., Davis S. Murray S.F., Yu X.X., Pandey S.K., Pear M., Watts L., Booten S.L., Graham M., McKay R., Subramaniam A., Propp S., Lollo B.A., Freier S., Bennett C.F., Bhanot S., Monia B.P. MiR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metabolism. 2006. Vol. 3. P. 87–98. doi: 10.1016/j.cmet.2006.01.005.

Lee R.C., Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science. 2001. 294. P. 862–864. doi: 10.1126/science.1065329. doi: 10.1126/science.1065329.

Lau N.C., Lim L.P., Weinstein E.G., Bartel D.P. An abundant class of tiny RNAs with probable regulatory roles in Caenor-habditis elegans. Science. 2001. Vol. 294. P. 858–862. doi: 10.1126/science.1065062.

Lagos-Quintana M., Rauhut R., Lendeckel W., Tuschl T. Identification of novel genes coding for small expressed RNAs. Science. 2001. Vol. 294. P. 853–858. doi: 10.1126/science.1064921.

Bartel D. MicroRNAs: target recognition and regulatory functions. Cell. 2009. Vol. 136. P. 215–233. doi: 10.1016/j.cell.2009.01.002.

Ciafrè S.A., Galardi S., Mangiola A., Ferracin M., Liu C.G., Sabatino G., Negrini M., Maira G., Croce C.M., Farace M.G.. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun. 2005. Vol. 334. P. 1351–1358. doi: 10.1016/j.bbrc.2005.07.030.

Wang K., Jia Z., Zou J., Zhang A., Wang G., Hao J., Wang Y., Yang S., Pu P. Analysis of hsa-miR-30a-5p expression in hu-man gliomas. Pathol Oncol Res. 2013. Vol. 19. P. 405–411. doi: 10.1007/s12253-012-9593-x.

Calin G.A., Liu C.G., Sevignani C., Ferracin M., Felli N., Dumitru C.D., Shimizu M., Cimmino A. Zupo S., Dono M., Dell’Aquila M.L., Alder H., Rassenti L., Kipps T.J., Bullrich F., Negrini M., Croce C.M. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA. 2004. Vol. 101. P. 11755–11760. doi: 10.1073/pnas.0404432101.

Volinia S., Calin G.A., Liu C.G., Ambs S., Cimmino A., Petrocca F., Visone R., Iorio M., Roldo C., Ferracin M., Prueitt R.L., Yanaihara N., Lanza G., Scarpa A., Vecchione A., Negrini M., Harris C.C., Croce C.M. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 2006. Vol. 103. P. 2257–2261. doi: 10.1073/pnas.0510565103.

Schetter A.J., Leung S.Y., Sohn J.J., Zanetti K.A., Bowman E.D., Yanaihara N., Yuen S.T., Chan T.L., Kwong D.L., Au G.K., Liu C.G., Calin G.A., Croce C.M., Harris C.C. MicroRNA expression profiles associated with prognosis and therapeutic out-come in colon adenocarcinoma. Jama. 2008. Vol. 299. P. 425–436. doi: 10.1001/jama.299.4.425.

Gardiner E., Beveridge N.J., Wu J.Q., Carr V., Scott R.J., Tooney P.A., Cairns M.J. Imprinted DLK1-DIO3 region of 14q32 defines a schizophrenia-associated miRNA signature in peripheral blood mononuclear cells. Mol Psychiatry. 2012. Vol. 17. P. 827–840. doi: 10.1038/mp.2011.78.

Belzeaux R., Bergon A., Jeanjean V., Loriod B., Formisano-Tréziny C., Verrier L, Loundou A, Baumstarck-Barrau K, Boyer L, Gall V, Gabert J, Nguyen C, Azorin JM, Naudin J, Ibrahim EC. Responder and nonresponder patients exhibit different peripheral transcriptional signatures during major depressive episode. Transl Psychiatry. 2012. 2. e185. doi: 10.1038/tp.2012.112.

Wei J., Zhang Y., Luo Y., Wang Z., Bi S., Song D., Dai Y., Wang T., Qiu L., Wen L., Yuan L., Yang J.Y. Aldose reductase regulates miR-200a-3p/141-3p to coordinate Keap1-Nrf2, Tgfβ1/2, and Zeb1/2 signaling in renal mesangial cells and the renal cortex of diabetic mice. Free Radic Biol Med. 2014. Vol. 67. P. 91–102. doi: 10.1016/j.freeradbiomed.2013.10.811.

Vilming Elgaaen B., Olstad O.K., Haug K.B., Brusletto B., Sandvik L., Staff A.C., Gautvik K.M., Davidson B. Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker. BMC Cancer. 2014. Vol. 14. P. 80. doi: 10.1186/1471-2407-14-80.

Roh M.S., Lee H.W., Jung S.B., Kim K., Lee E.H., Park M.I., Lee J.S., Kim M.S. Expression of miR-200c and its clinicopa-thological significance in patients with colorectal cancer. Pathol Res Pract. 2018. Vol. 214. P. 350–355. doi: 10.1016/j.prp.2018.01.00.

Wilczynski M., Danielska J., Domanska-Senderowska D., Dzieniecka M., Szymanska B., Malinowski A. Association of mi-croRNA-200c expression levels with clinicopathological factors and prognosis in endometrioid endometrial cancer. Acta Ob-stet Gynecol Scand. 2018. Vol. 97. P. 560–569. doi: 10.1111/aogs.13306.